ArticleAnnals of medicine and surgery (2012)2026
Effects of crocin on anxiety, depression, and hippocampal BDNF expression in streptozotocin-induced diabetic rats.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Crocin possesses anti-inflammatory and antioxidant properties. Objective: This study investigated the effects of crocin on anxiety- and depressive-like behaviors and its association with hippocampal brain-derived neurotrophic factor (BDNF) expression in streptozotocin (STZ)-induced diabetic rats. Methods: Twenty-eight male Wistar rats were divided into three groups: Control (citrate buffer + distilled water), Diabetes (STZ + distilled water), and Diabetes + Crocin (STZ + crocin 30 mg/kg) for 42 days. Behavioral tests, including open field, elevated plus-maze, forced swim, and tail suspension, were conducted on days 21 and 42. Hippocampal levels of catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx), and malondialdehyde (MDA) were measured, and BDNF expression was assessed. Results: Crocin significantly reduced anxiety-like behavior in the elevated plus-maze and depressive-like behavior in the forced swim and tail suspension tests. It improved hippocampal antioxidant status, with increased CAT, SOD, and GPx levels and decreased MDA levels. Crocin also enhanced BDNF expression in the hippocampus. Crocin ameliorates oxidative stress and elevates hippocampal BDNF, leading to reduced anxiety- and depressive-like behaviors in diabetic rats. Conclusion: These findings suggest crocin as a potential therapeutic agent for behavioral and molecular complications associated with diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.